Rahul Komati, MD
Retina Specialist · Chicago, ILNPI 1164840906
Payments from drug & device makers
Across 404 payments — averaging $352.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$115K
- Alimera Sciences, Inc.$12K
- Notal Vision, Inc.$2K
- Genentech USA, Inc.$2K
- Apellis Pharmaceuticals, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$2K
- plus $7K from 14 others
What the payments were for
- Consulting fees$2,3312%
- Speaking & faculty fees$110,03177%
- Travel & lodging$14,82710%
- Food & beverage$15,26911%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 127 | $115,153 |
| Alimera Sciences, Inc. | 48 | $12,151 |
| Notal Vision, Inc. | 8 | $2,319 |
| Genentech USA, Inc. | 56 | $2,099 |
| Apellis Pharmaceuticals, Inc. | 35 | $2,020 |
| Regeneron Healthcare Solutions, Inc. | 50 | $1,935 |
| Cardinal Health 108 LLC | 1 | $1,575 |
| AbbVie(2 entities) | 32 | $1,377 |
| Novartis | 15 | $1,139 |
| Regeneron | 3 | $823 |
| ANI Pharmaceuticals, Inc. | 10 | $524 |
| Bausch & Lomb Americas Inc. | 5 | $348 |
| Alcon | 2 | $296 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $141 |
| Mallinckrodt Enterprises LLC | 1 | $127 |
| Harrow Eye, LLC | 1 | $125 |
| Spark Therapeutics, Inc. | 1 | $125 |
| Biogen | 1 | $112 |
| Eyepoint US, Inc. | 4 | $76 |
| Coherus Oncology, Inc. | 2 | $51 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$142,516 in reported general payments places this provider in the 85th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 154 | $7,413 |
| Brimonidine Tartrate | 36 | $1,789 |
| Atropine Sulfate | 46 | $1,485 |
| Ketorolac Tromethamine | 33 | $1,254 |
| Ciprofloxacin Hcl | 45 | $503 |
| Latanoprost | 31 | $478 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 41 | $455 |
| Dorzolamide Hcl | 17 | $279 |
| Timolol Maleate | 32 | $192 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Chicago
- Veena RaijiChicago$308K
- Paulpoj ChiranandChicago$36K
- Jeffrey ParnellChicago$27K
- Henry FengChicago$16K
- Shaun IttiaraChicago$9K
- Sarah SyedaChicago$6K
- Saagar PanditChicago$6K
- Daniel BalikovChicago$3K
- Emily ShepherdChicago$3K
- John WilguckiChicago$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.